Hey, what do you know, we finally found something to agree on, lol.
btw, it's not that I don't understand the risks, it's just that I disagree with your conclusion that it's a crap-shoot. 90% of pts in the P2 were progressing at enrollment and yet rida reached nearly a 30% PFS. Rida performed best in those subtypes that also tend to do well with chemo, ergo, those sarcomas are more likely to have been included in the P3 which doesn't make it a slam dunk but certainly makes it less of a crapshoot.
Also, my complaint with analysts is that if you are going to conclude that the difference in pfs is a matter of weeks then at least have the courage of your convictions and conclude that the trial is likely to fail. Personally, I don't think that's going to be the case but we'll know soon enough.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.